JMJD3 and SNAI2 synergistically protect against Parkinson’s disease by mediating the YAP/HIF1α signaling pathway in a mouse model
Human Molecular Genetics · 2023
DOI: 10.1093/hmg/ddad115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2023. Verfasst von Li Dong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China. Hauptthemen laut MEDLINE: Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor 1, alpha Subunit, Snail Family Transcription Factors, Parkinson Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
This study aimed to characterize the functional relevance and mechanistic basis of the histone demethylase Jumonji domain-containing protein-3 (JMJD3) in preserving dopaminergic neuron survival in Parkinson’s disease (PD). Mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced lesions and MN9D dopaminergic neuronal cell lines exposed to 6-OHDA, respectively, were used to simulate in vivo and in vitro PD-like environments. PD-related genes with differential expressions were identified using RNA sequencing of hippocampal tissues collected from MPTP-lesioned mice. A specific lentiviral shRNA vector was used to investigate the effects of JMJD3 on neuron activities in vitro and PD-like phenotypes in vivo. JMJD3 was found to up-regulate the expression of Snail family transcriptional repressor 2 (SNAI2) through the inhibition of H3 on lysine 27 (H3K27me3) enrichment in the SNAI2 promoter region. As a result, the viability of 6-OHDA-exposed MN9D cells was stimulated, and cell apoptosis was diminished. Knockdown of SNAI2 decreased the expression of yes-associated protein (YAP) and HIF1α while also reducing the viability of 6-OHDA-exposed MN9D cells and increasing cell apoptosis. The in vivo experiments demonstrated that JMJD3 activated the SNAI2/YAP/HIF1α signaling pathway, inhibiting PD-like phenotypes in MPTP-lesioned mice. Thus, the findings provide evidence that JMJD3 inhibits the enrichment of H3K27me3 at the SNAI2 promoter, leading to the upregulation of SNAI2 expression and activation of the YAP/HIF1α signaling pathway, ultimately exerting a protective effect on PD mice. This finding suggests that targeting the JMJD3-SNAI2 pathway could be a promising therapeutic strategy for PD. Further in-depth studies are needed to elucidate the underlying mechanisms and identify potential downstream targets of this pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
ORCID-Profile: Lianbo Gao
Zitieren
APA
Dong, L., & Gao, L. (2023). JMJD3 and SNAI2 synergistically protect against Parkinson’s disease by mediating the YAP/HIF1α signaling pathway in a mouse model. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddad115
Vancouver
Dong L, Gao L. JMJD3 and SNAI2 synergistically protect against Parkinson’s disease by mediating the YAP/HIF1α signaling pathway in a mouse model. Human Molecular Genetics. 2023. doi:10.1093/hmg/ddad115
BibTeX
@article{Dong2023,
author = {Dong, Li and Gao, Lianbo},
title = {JMJD3 and SNAI2 synergistically protect against Parkinson’s disease by mediating the YAP/HIF1α signaling pathway in a mouse model},
journal = {Human Molecular Genetics},
year = {2023},
doi = {10.1093/hmg/ddad115}
}
EUVIMED